Increased macrophage migration inhibitory factor in Behçet's disease and relation with the disease activity

Serarslan, Gamze; Söğüt, Sadık; Yönden, Zafer; Öksüz, Hafize; Savaş, Nazan; Yenin, JZ; Arpacı, Abdullah

doi:10.1111/j.1468-3083.2009.03223.x

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the mean MIF levels in the sera of patients with Behçet’s uveitis and iridocyclitis were found to be higher than those of healthy control subjects [22, 23]. Also, it was reported that the mean serum level of MIF in patients with BD was higher in patients with BD than in healthy controls [24, 25]. …”

Section: Discussionmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor –173GC Variant Might Increase the Risk of Behçet’s Disease

et al. 2018

View full text Add to dashboard Cite

Objective: The aim of the present study was to investigate any possible association between the macrophage migration inhibitory factor (MIF) –173GC variant and Behçet’s disease (BD) in a group of Turkish patients. Subjects and Methods: A total of 111 patients with BD and 100 healthy controls were enrolled in this study. Genomic DNA was extracted from peripheral lymphocytes. The MIF –173GC variant was genotyped using polymerase chain reaction restriction fragment length polymorphism. The allele and genotype frequencies of patients and controls were compared using the χ² test. Results: A statistically significant difference in the distribution of the genotype was observed between BD patients and healthy controls. The homo-genotype CC was more prevalent in the patient group compared to the control group (p = 0.008, OR: 0.24, 95% Cl: 0.05–0.78). A significant association was observed when the patients were compared with the controls according to GG + GC versus CC genotypes (p = 0.003, OR: 1.21, 95% CI: 0.06–0.063). Allele frequencies of the MIF −173GC variant did not show any statistically significant difference between patients and controls. Conclusion: In this study, we conclude that the CC genotype of the MIF –173GC variant may be a risk factor in the pathogenesis of BD in the Turkish population. However, further studies with larger samples are needed to address the exact role of this variant in BD.

show abstract

Section: Discussionmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor –173GC Variant Might Increase the Risk of Behçet’s Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Hatemi

Merkel²,

Hamuryudan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

Behçet syndrome (BS) is a multisystem vasculitis that is most active during young adulthood, causing serious disability and significant impairment in quality of life. Differences in the disease course, severity, and organ involvement between patients, depending on the age at presentation and sex, makes it impossible to determine a single management strategy. The diversity and variability in the outcome measures used in clinical trials in BS makes it difficult to compare the results or inform physicians about the best management strategy for individual patients. There is a large unmet need to determine or develop validated outcome measures for use in clinical trials in BS that are acceptable to researchers and regulatory agencies. We conducted a systematic review to describe the outcomes and outcome measures that have been used in clinical trials in BS. This review revealed the diversity and variability in the outcomes and outcome measures and the lack of standard definitions for most outcomes and rarity of validated outcome tools for disease assessment in BS. This systematic literature review will identify domains and candidate instruments for use in a Delphi exercise, the next step in the development of a core set of outcome measures that are properly validated and widely accepted by the collaboration of researchers from many different regions of the world and from different specialties, including rheumatology, ophthalmology, dermatology, gastroenterology, and neurology.

show abstract

Increased macrophage migration inhibitory factor in Behçet's disease and relation with the disease activity

Cited by 2 publications

References 7 publications

Macrophage Migration Inhibitory Factor –173GC Variant Might Increase the Risk of Behçet’s Disease

Macrophage Migration Inhibitory Factor –173GC Variant Might Increase the Risk of Behçet’s Disease

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Contact Info

Product

Resources

About